Personalized fusion cell vaccines
Inventors
Avigan, David • ROSENBLATT, Jacalyn • Kufe, Donald
Assignees
Dana Farber Cancer Institute Inc • Beth Israel Deaconess Medical Center
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12758631-B2
Publication Date
2026-10-13
Expiration Date
Abstract
The present invention provides compositions and methods for treating cancer.
Core Innovation
The described invention combines CAR-T cells with fusion-vaccine-educated T cells in a T-cell composition for lymphoma treatment. The educated T cells arise from co-culture with a fusion of dendritic and lymphoma cells [procedural detail omitted for safety]. The composition includes cells that target an antigen expressed by the lymphoma. The description also identifies an alginate/RGD/4-1BBL biomatrix and agonistic 4-1BB stimulation as T-cell-supporting approaches.
The background section is not included, so the technical problem is not explicitly available in the provided text. In the A20 lymphoma model, the combination increases tumor-cell killing and reduces tumor burden. Additionally, fusion-vaccine co-culture improves CAR-T expansion, persistence, and antigen-specific responses while inducing a memory-like phenotype. Evaluated outcomes encompass animal tumor-growth and survival metrics alongside clinical observations.
Claims Coverage
The claims identify five inventive features directed to lymphoma treatment using a composition of CAR-T cells and educated T cells, encompassing independent and dependent claim elements.
Lymphoma treatment with a T-cell composition
A method of treating lymphoma in a subject by administering a T-cell composition comprising CAR-T cells and educated T cells obtained by co-culturing T cells with a dendritic-cell and lymphoma-cell fusion cell [procedural detail omitted for safety], wherein the cells target an antigen expressed by the lymphoma.
Biomatrix-assisted T-cell education
A claim specifies a biomatrix comprising alginate, RGD peptide, and 4-1BBL alongside the fusion cell in obtaining educated T cells.
Specified CAR-T target antigens
A claim specifies CAR-T cells directed against CD-19 or BCMA.
Additional 4-1BB-directed treatment component
A claim adds administration of an agonistic 4-1BB antibody or an antigen-binding fragment thereof.
Educated CAR-T cells and autologous dendritic cells
Claims specify educated CAR-T cells obtained by transducing educated T cells with a CAR and specify that the dendritic cell is autologous to the subject.
The claims center on lymphoma treatment using a composition of CAR-T cells and fusion-cell-educated T cells, with dependent claims specifying biomatrix components, target antigens, 4-1BB-directed co-treatments, educated CAR-T transduction, and autologous cell sources.
Stated Advantages
The combination increases tumor-cell killing and reduces tumor burden in the A20 lymphoma model.
Fusion-vaccine co-culture improves CAR-T expansion and persistence, induces a memory-like phenotype, and increases antigen-specific T-cell responses.
Documented Applications
Treatment of lymphoma in a subject using a T-cell composition comprising CAR-T cells and educated T cells.
Evaluation of the cell combination in the A20 lymphoma model.
Clinical observations and trial evaluations concerning relapsed multiple myeloma.
Interested in licensing this patent?